透析中低血压的机制、临床意义与治疗
本文综述维持性血液透析患者透析中低血压的相关证据,指出超滤常需清除相当于整个血浆容量的液体,代偿机制常因患者及透析因素不足而失效,导致透析中低血压并与心血管及全因死亡率升高相关,并基于病理生理提出防治策略。
要点
- 透析中超滤量常相当于整个血浆容量,代偿不足可致透析中低血压。
- 透析中低血压与心血管死亡及全因死亡升高相关。
- 防治策略应基于对透析中低血压病理生理的理解。
核心结论
- 透析中低血压与心血管死亡及全因死亡升高相关。
- 代偿机制因患者及透析相关因素常不足以维持终末器官灌注。
研究设计与样本
- 综述,总结透析中低血压不良结局证据并探讨病理生理及防治策略。
主要发现
- 超滤目标常涉及清除相当于整个血浆容量的液体。
- 多种代偿机制共同维持透析中终末器官灌注。
- 患者及透析相关因素可致代偿不足而发生透析中低血压。
临床怎么用
- 基于病理生理机制制定透析中低血压的预防与治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Individuals with ESKD requiring maintenance hemodialysis face a unique hemodynamic challenge, typically on a thrice-weekly basis. In an effort to achieve some degree of euvolemia, ultrafiltration goals often involve removal of the equivalent of an entire plasma volume. Maintenance of adequate end-organ perfusion in this setting is dependent on the institution of a variety of complex compensatory mechanisms. Unfortunately, secondary to a myriad of patient- and dialysis-related factors, this compensation often falls short and results in intradialytic hypotension. Physicians and patients have developed a greater appreciation for the breadth of adverse outcomes associated with intradialytic hypotension, including higher cardiovascular and all-cause mortality. In this review, we summarize the evidence for adverse outcomes associated with intradialytic hypotension, explore the underlying pathophysiology, and use this as a basis to introduce potential strategies for its prevention and treatment.
引用
- Reeves PB, Mc Causland FR. Mechanisms, Clinical Implications, and Treatment of Intradialytic Hypotension. Clin J Am Soc Nephrol. 2018. PMID: 29483138. doi:10.2215/CJN.12141017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。